The New York City-based drugmaker first considered the split in early 2014, when it decided to operate its generic and brand name drug businesses as two separate divisions. Pfizer planned to track each sector’s progress for three years before making a final decision on the split.
According to Pfizer’s internal analysis, the split offered no benefits to shareholders. Tax costs and business disruptions also weighed into the decision.
The company originally considered the split since its patent-protected drugs showed strong sales growth, while its generic division saw sales decline, according to the report.
More articles on supply chain:
Mylan working on EpiPen formulation with longer shelf life
FDA fast tracks malaria vaccine
Big-box distribution centers on the rise: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
